Pharmaceutical Technology, Aug 1, 2014 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Aug 1, 2014
Outsourcing
Positive Outlook for Outsourcing
By Jim Miller
Contract services ride high as funding floods bio/pharma.
Featured Content
Shifting Gears in Drug Development Outsourcing Responsibilities
By Rita Peters
For a bio/pharma industry in flux, contract services are playing a greater—and more diverse—role in drug development.
Quality by Design in Contract Service Relationships
Contract service providers describe how quality by design has influenced a drug sponsor's expectations of suppliers.
Analytical Labs Strive to Deliver More Information, Faster
Experts from contract testing laboratories and service organizations shared their perceptions of analytical testing advances, and challenges still ahead.
Technologies Key for Biologics to Meet Expectations
Representatives of contract service organizations that develop biologic-based drugs discussed technology trends such as high-throughput screening and single-use systems.
Solid-Dosage Forms Demand Traditional and Emerging Technologies
Contract development and manufacturing organizations identify trends, challenges, and emerging technology and service needs for solid and semi-solid dosage forms.
CMOs Target Parenteral Drug Development Needs Both Large and Small
Representatives of contract service organizations that specialize in parenteral drug development and manufacturing describe the evolving trends.
Contractors Invest in Capacity and Capabilities
Contract research, development, and manufacturing organizations invested in new facilities and technologies in 2014 for analytical testing, as well as small- and large-molecule drug development.
Weighing Clinical Trial Outsourcing Options
By Bryan Haas , Dave Agrella , Scott Maisto
Evolving clinical trial research services give biopharmaceutical companies options for full and functional services.
Europe's Need for Early Development Pharmaceutical Manufacturing Expertise
By Jon Sutch
Despite the growth of specialist companies with capabilities across various therapeutic areas in Europe, there is still a need for early development expertise with end-to-end pharmaceutical manufacturing capabilities.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here